Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HGP0918 + HGP0816
- Development stage
- Unknown
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HGP0918 + HGP0816 is an investigational oral fixed-dose combination of two small molecule drugs developed by Hanmi Pharmaceutical. The combination has been studied primarily for its pharmacokinetic interactions and safety profile in healthy adult subjects and patients with hyperlipidemia. Both components are being evaluated as part of Hanmi's broader research into novel therapies for metabolic diseases, particularly dyslipidemia/hyperlipidemias. The mechanism of action and specific targets for each component have not been publicly disclosed as of the latest available data, but the combination is intended to address lipid disorders.
Beyond the preview
Go deeper on HGP0918 + HGP0816.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HGP0918 + HGP0816.